Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. (otvara novi prozor)

Barillari G, Pasca S, Barillari A, De Angelis V.

Izvor‎: Blood Transfus 2012;10(1):87-94.

Indeks‎: PubMed 22044952

DOI‎: 10.2450/2011.0030-11

https://www.ncbi.nlm.nih.gov/pubmed/22044952 (otvara novi prozor)

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (otvara novi prozor)

Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R; American College of Chest Physicians.

Izvor‎: Chest 2012;141(2 Suppl):e326S-50S.

Indeks‎: PubMed 22315266

DOI‎: 10.1378/chest.11-2298

https://www.ncbi.nlm.nih.gov/pubmed/22315266 (otvara novi prozor)

Pharmacological prophylaxis of bleeding in surgical patients treated with aspirin. (otvara novi prozor)

Flordal PA.

Izvor‎: Eur J Anaesthesiol Suppl 1997;14:38-41.

Indeks‎: PubMed 9088834

https://www.ncbi.nlm.nih.gov/pubmed/9088834 (otvara novi prozor)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (otvara novi prozor)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Izvor‎: Lancet 2015;385(9982):2077-87.

Indeks‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (otvara novi prozor)

How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. (otvara novi prozor)

Goodnough LT, Shander A.

Izvor‎: Blood 2011;117(23):6091-9.

Indeks‎: PubMed 21411756

DOI‎: 10.1182/blood-2010-11-316075

https://www.ncbi.nlm.nih.gov/pubmed/21411756 (otvara novi prozor)

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. (otvara novi prozor)

Hanke AA, Joch C, Görlinger K.

Izvor‎: Br J Anaesth 2013;110(5):764-72.

Indeks‎: PubMed 23335567

DOI‎: 10.1093/bja/aes501

https://www.ncbi.nlm.nih.gov/pubmed/23335567 (otvara novi prozor)

Reversing the effects of antiplatelet agents in the setting of intracranial hemorrhage: a look at the literature. (otvara novi prozor)

Jaben EA, Mulay SB, Stubbs JR.

Izvor‎: J Intensive Care Med 2015;30(1):3-7.

Indeks‎: PubMed 25492811

DOI‎: 10.1177/0885066613487298

https://www.ncbi.nlm.nih.gov/pubmed/25492811 (otvara novi prozor)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (otvara novi prozor)

Levi M, Eerenberg E, Kamphuisen PW.

Izvor‎: J Thromb Haemost 2011;9(9):1705-12.

Indeks‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (otvara novi prozor)

Emergency reversal of warfarin anticoagulation. (otvara novi prozor)

Lin Y, Callum J.

Izvor‎: CMAJ 2010;182(18):2004.

Indeks‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (otvara novi prozor)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (otvara novi prozor)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Izvor‎: Thromb Haemost 2012;108(2):217-24.

Indeks‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (otvara novi prozor)

Recent advances in the development of specific antidotes for target-specific oral anticoagulants. (otvara novi prozor)

Mo Y, Yam FK.

Izvor‎: Pharmacotherapy 2015;35(2):198-207.

Indeks‎: PubMed 25644580

DOI‎: 10.1002/phar.1532

https://www.ncbi.nlm.nih.gov/pubmed/25644580 (otvara novi prozor)

Idarucizumab for dabigatran reversal - full cohort analysis. (otvara novi prozor)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Izvor‎: N Engl J Med 2017;377(5):431-41.

Indeks‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (otvara novi prozor)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (otvara novi prozor)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Izvor‎: Anesth Analg 2011;113(4):703-10.

Indeks‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (otvara novi prozor)

Oral anticoagulation in surgical procedures: risks and recommendations. (otvara novi prozor)

Torn M, Rosendaal FR.

Izvor‎: Br J Haematol 2003;123(4):676-82.

Indeks‎: PubMed 14616972

https://www.ncbi.nlm.nih.gov/pubmed/14616972 (otvara novi prozor)

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. (otvara novi prozor)

Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW.

Izvor‎: Blood 2012;119(9):2172-4.

Indeks‎: PubMed 22383791

DOI‎: 10.1182/blood-2011-11-393587

https://www.ncbi.nlm.nih.gov/pubmed/22383791 (otvara novi prozor)